Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$11.75 ▼ -0.18
(-1.51%)
MKT CAP: $2.01B • VOL: 1.42M
52W L $5 52W H $12
VIR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $68.6M | $74.2M | $86.2M |
| YoY Revenue Growth % | -7.6% | -13.9% | — |
| Gross Profit | $68.5M | $73.4M | — |
| Gross Margin % | 98.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$479.3M | -$587.2M | -$684.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$438.0M | -$522.0M | -$615.1M |
| EBITDA (Normalized) | -$475.5M | -$581.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$391.8M | -$446.4M | -$778.8M |
| Capital Expenditures (CapEx) | $4.8M | $7.3M | — |
| Free Cash Flow (FCF) | -$396.6M | -$453.7M | -$778.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $232.2M | $222.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $765.3M | $1.15B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VIR.